Compare Eli Lilly And Co (LLY) vs Palantir Technologies Inc (PLTR) Price & Performance

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Palantir (PLTR) trades at $175.20, up 1.85% with strong bullish technical signals and consistent earnings beats. The stock shows impressive fundamental growth with revenue reaching $4.48 billion in 2025 and net income margin expanding to 36.3%. Recent quarterly EPS results have exceeded expectations, driving positive investor sentiment despite elevated valuation multiples. Technical indicators show bullish momentum with the current price near pivot point resistance at $175.

Outlook remains positive with accelerating revenue growth and expanding margins, though high valuation ratios (P/E 149.52, P/S 73.07) present risk. Analyst consensus targets $213.44 with 50% buy ratings, but insider selling and Michael Burry's bearish stance highlight caution. The stock offers growth potential but requires monitoring of execution risks and competitive pressures in the AI software space.